Company Description
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.
It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI.
The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.
Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Richard Paolone |
Contact Details
Address: 777 Yamato Road, Suite 502 Boca Raton, Florida 33431 United States | |
| Phone | 561 589 7020 |
| Website | enterothera.com |
Stock Details
| Ticker Symbol | ENTO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604191 |
| CUSIP Number | 33749P507 |
| ISIN Number | US33749P5070 |
| Employer ID | 46-4993860 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Joel Paolone | Interim Chief Executive Officer and Chairman |
| Anna Skowron | Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 15, 2025 | EFFECT | Notice of Effectiveness |
| Sep 12, 2025 | 8-K | Current Report |
| Sep 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 9, 2025 | 8-K | Current Report |
| Aug 26, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 26, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 18, 2025 | D | Notice of Exempt Offering of Securities |
| Aug 15, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |